Isofraxidin exhibited anti-inflammatory effects in vivo and inhibited TNF-α production in LPS-induced mouse peritoneal macrophages in vitro via the MAPK pathway

Niu, Xiaofeng; Wei, Xing; Liu, Weifeng; Fan, Ting; Hu, Hua; Li, Yongmei

doi:10.1016/j.intimp.2012.06.022

Cited by 77 publications

(45 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…TNF-␣ is the first cytokine to be released in the initiation of LPS, and also plays a key role in inducing IL-6 and IL-12 production (Heinzel et al, 1994;Suzuki et al, 2000). Our previous findings showed that IF can inhibit TNF-␣ production in serum via the MAPK pathway (Niu et al, 2012). In the present study, pretreatment with IF reduced the level of TNF-␣ in liver in a dose-dependent manner compared to the LPS group, suggesting that the liver is the major source of TNF-␣ production (Kumins et al, 1996).…”

Section: Discussionmentioning

confidence: 99%

“…Recent research has suggested that IF acts at a transcriptional level to regulate inflammatory modulators such as NF-B and IBs, which could then affect downstream genes involved in the inflammatory response, including iNOS, COX-2 and TNF-␣. Our previous study showed that the in vivo and in vitro antiinflammatory effects of IF are mediated via regulation of the MAPK pathway and inhibition TNF-␣ in serum (Niu et al, 2012). Since the effect of IF may play an important role in disease therapy, we investigated whether IF would attenuate the production of TNF-␣ in liver, IL-6, NO in serum and histopathological changes following LPS stimulation.…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Isofraxidin protects mice from LPS challenge by inhibiting pro-inflammatory cytokines and alleviating histopathological changes

Liu

et al. 2015

Immunobiology

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 98%

Isofraxidin protects mice from LPS challenge by inhibiting pro-inflammatory cytokines and alleviating histopathological changes

Liu

et al. 2015

Immunobiology

Self Cite

View full text Add to dashboard Cite

“…Niu et al . [20] examined that arthritic mice treated with isofraxidin (IF) had an obvious difference in serum tumor necrosis factor-α (TNF-α) compared with the lipopolysaccharides-stimulated group, IF may possess significant anti-inflammatory activities. Astilbin isolated from Rhizoma Smilacis Glabrae , inhibited the footpad swelling, arthritic incidence, and clinical scores without losing body weight [21].…”

Section: Discussionmentioning

confidence: 99%

Chinese medicine combined with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris (CMCBCOP): study protocol for a randomized controlled trial

Wen

Xuan²,

Yan³

et al. 2014

Trials

View full text Add to dashboard Cite

BackgroundPsoriasis causes worldwide concern because of its high-prevalence, as well as its harmful, and incurable characteristics. Topical therapy is a conventional treatment for psoriasis vulgaris. Chinese medicine (CM) has been commonly used in an integrative way for psoriasis patients for many years. Some CM therapies have shown therapeutic effects for psoriasis vulgaris (PV), including relieving symptoms and improving quality of life, and may reduce the relapse rate. However, explicit evidence has not yet been obtained. The purpose of the present trial is to examine the efficacy and safety of the YXBCM01 granule, a compound Chinese herbal medicine, with a combination of topical therapy for PV patients.Methods/DesignUsing an add-on design, the trial is to evaluate whether the YXBCM01 granule combined topical therapy is more effective than topical therapy alone for the treatment of PV. The study design is a double-blind, parallel, randomized controlled trial comparing the YXBCM01 granule (5.5 g twice daily) to a placebo. The duration of treatment is 12 weeks. A total of 600 participants will be randomly allocated into two groups, YXBCM01 granule group and placebo group, from 11 general or dermatological hospitals in China. Topical use of calcipotriol betamethasone for the first 4 weeks and calcipotriol ointment for the remaining 8 weeks will be the same standard therapy for the two groups. Patients will be enrolled if they have a clinical diagnosis of PV, a psoriasis area severe index (PASI) of more than 10 or body surface area (BSA) of more than 10%, but PASI of less than 30 and BSA of less than 30%, are aged between 18 and 65-years-old, and provide signed informed consent. The primary outcome, relapse rate, is based on PASI assessed blindly during the treatment. Secondary outcomes include: (i) relapse time interval, (ii) time to onset, (iii) rebound rate, (iv) PASI score, (v) cumulative consumption of medicine, (vi) the dermatology quality life index (DLQI), and (vii) the medical outcomes study (MOS) item short form health survey (SF-36). Analysis will be on intention-to-treat and per-protocol subject analysis principles.DiscussionTo address the effectual remission of the YXBCM01 granule for PV, this trial may provide a novel regimen for PV patients if the granule can decrease relapse rate without more adverse effects.Trial registrationChinese Clinical Trial Registry (http://cwww.chictr.org): ChiCTR-TRC-13003233, registered 26 May 2013.

show abstract

“…Mitogen-activated protein kinase (MAPK) plays pivotal role in LPS-induced activation of pro-inflammatory cytokines, and inhibition of its activity can abolish LPS-induced activation of TNF-α (Kirchner et al 2004;Shen et al 2005;Niu et al 2012). The activation status of MAPKs was tested in cells pretreated with the extract and stimulated with LPS.…”

Section: Treatment With Fermented Bitter Gourd Extract Suppressed Lpsmentioning

confidence: 99%

Fermented bitter gourd extract differentially regulates lipopolysaccharide-induced cytokine gene expression through nuclear factor-κB and interferon regulatory factor-1

Jang

Lim

Lee

et al. 2015

Animal Cells and Systems

View full text Add to dashboard Cite

Bitter gourd is the fruit of a tropical vine in Asia, Africa, and South America where it is commonly used in traditional medicine. Our study tested the effects of a fermented extract of the bitter gourd on the inflammatory activities of the human monocytic leukemia cell line, THP-1. Treatment with the extract resulted in the suppression of phagocytic as well as lipopolysaccharide (LPS)-induced adhesion activity. Interestingly, the LPS-induced expression of matrix metalloproteinase-9 (MMP-9) and tumor necrosis factor-α (TNF-α) was suppressed by the extract while the expression of Interleukin-8 (IL-8) was upregulated. The extract inhibited the LPS-induced activation of p38 mitogen-activated protein kinase (MAPKs) and nuclear factor-κB (NF-κB), both of which are well known to be required for the expression of MMP-9 and TNF-α. In contrast, the expression of interferon regulatory factor (IRF) 1, a transcription factor involved in the expression of IL-8, but not TNF-α, was enhanced by the extract. Suppression of IRF-1 expression resulted in the elimination of the extract's interleukin-8 (IL-8) enhancing effect. These results indicate that the fermented bitter gourd extract has general anti-inflammatory effects, with a differential effect on the expression of cytokines through modulation of NF-κB and IRF-1 activities.

show abstract

Isofraxidin exhibited anti-inflammatory effects in vivo and inhibited TNF-α production in LPS-induced mouse peritoneal macrophages in vitro via the MAPK pathway

Cited by 77 publications

References 43 publications

Isofraxidin protects mice from LPS challenge by inhibiting pro-inflammatory cytokines and alleviating histopathological changes

Isofraxidin protects mice from LPS challenge by inhibiting pro-inflammatory cytokines and alleviating histopathological changes

Chinese medicine combined with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris (CMCBCOP): study protocol for a randomized controlled trial

Fermented bitter gourd extract differentially regulates lipopolysaccharide-induced cytokine gene expression through nuclear factor-κB and interferon regulatory factor-1

Contact Info

Product

Resources

About